Objective This study is to analyze the data of Chinese subpopulation in the Tarceva Lung
Cancer Survival Treatment Study (TRUST-China) which was a global Phase IV study …

Introduction The aim of this study was to evaluate the efficacy and safety of Erlotinib in
Japanese patients with previously treated non-small cell lung cancer (NSCLC). Available …

Introduction: Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor that
significantly increases survival for patients with previously treated advanced non-small cell …

ABSTRACT< p>< b> OBJECTIVE</b> To observe the efficacy and the adverse effects of
erlotinib in the treatment for advanced non-small cell lung cancer (NSCLC) in Chinese …

Methods An open labeled, expanded access program (EAP) was conducted on 44
pathologically confirmed advanced NSCLC patients who had received at least one regimen …

Background Erlotinib (Tarceva, OSI Pharmaceuticals, Melville, NY) is an oral, epidermal
growth factor receptor tyrosine kinase inhibitor that has antitumor activity and good …

Background: Erlotinib is a standard of treatment for metastatic non-small-cell lung cancer
after failure of initial therapy. Patient selection based on clinical factors is under discussion …

Objective Erlotinib is a small-molecule inhibitor of EGFR tyrosine kinase, showing a
significant improvement of survival in non-small-cell lung cancer (NSCLC) after the failure of …

Background A retrospective analysis of clinical data were conducted reviewing patients who
were given erlotinib at Peking Union Medical College (PUMC) Hospital from May 2005 to …

BACKGROUND. Erlotinib is an orally available, reversible inhibitor of epidermal growth
factor receptor (EGFR) with a proven survival advantage for patients with locally advanced …